A data-informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data
© 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd..
Pharmaceutical claims data are often used as the primary information source to define medicine exposure periods in pharmacoepidemiological studies. However, often critical information on directions for use and the intended duration of medicine supply are not available. In the absence of this information, alternative approaches are needed to support the assignment of exposure periods. This study summarises the key methods commonly used to estimate medicine exposure periods and dose from pharmaceutical claims data; and describes a method using individualised dispensing patterns to define time-dependent estimates of medicine exposure and dose. This method extends on important features of existing methods and also accounts for recent changes in an individual's medicine use. Specifically, this method constructs medicine exposure periods and estimates the dose used by considering characteristics from an individual's prior dispensings, accounting for the time between prior dispensings and the amount supplied at prior dispensings. Guidance on the practical applications of this method is also provided. Although developed primarily for application to databases, which do not contain duration of supply or dose information, use of this method may also facilitate investigations when such information is available and there is a need to consider individualised and/or changing dosing regimens. By shifting the reliance on prescribed duration and dose to determine exposure and dose estimates, individualised dispensing information is used to estimate patterns of exposure and dose for an individual. Reflecting real-world individualised use of medicines with complex and variable dosing regimens, this method offers a pragmatic approach that can be applied to all medicine classes.
| Errataetall: |
ErratumIn: Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5714. - PMID 37833051 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Pharmacoepidemiology and drug safety - 32(2023), 3 vom: 09. März, Seite 352-365 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bharat, Chrianna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug utilization |
|---|
| Anmerkungen: |
Date Completed 16.02.2023 Date Revised 20.03.2024 published: Print-Electronic ErratumIn: Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5714. - PMID 37833051 Citation Status MEDLINE |
|---|
| doi: |
10.1002/pds.5567 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348595980 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348595980 | ||
| 003 | DE-627 | ||
| 005 | 20240320232852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/pds.5567 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM348595980 | ||
| 035 | |a (NLM)36345837 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bharat, Chrianna |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A data-informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5714. - PMID 37833051 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. | ||
| 520 | |a Pharmaceutical claims data are often used as the primary information source to define medicine exposure periods in pharmacoepidemiological studies. However, often critical information on directions for use and the intended duration of medicine supply are not available. In the absence of this information, alternative approaches are needed to support the assignment of exposure periods. This study summarises the key methods commonly used to estimate medicine exposure periods and dose from pharmaceutical claims data; and describes a method using individualised dispensing patterns to define time-dependent estimates of medicine exposure and dose. This method extends on important features of existing methods and also accounts for recent changes in an individual's medicine use. Specifically, this method constructs medicine exposure periods and estimates the dose used by considering characteristics from an individual's prior dispensings, accounting for the time between prior dispensings and the amount supplied at prior dispensings. Guidance on the practical applications of this method is also provided. Although developed primarily for application to databases, which do not contain duration of supply or dose information, use of this method may also facilitate investigations when such information is available and there is a need to consider individualised and/or changing dosing regimens. By shifting the reliance on prescribed duration and dose to determine exposure and dose estimates, individualised dispensing information is used to estimate patterns of exposure and dose for an individual. Reflecting real-world individualised use of medicines with complex and variable dosing regimens, this method offers a pragmatic approach that can be applied to all medicine classes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a drug utilization | |
| 650 | 4 | |a methods | |
| 650 | 4 | |a pharmacoepidemiology | |
| 650 | 4 | |a treatment episodes | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Degenhardt, Louisa |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Sallie-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Buizen, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Dobbins, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Gisev, Natasa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacoepidemiology and drug safety |d 1996 |g 32(2023), 3 vom: 09. März, Seite 352-365 |w (DE-627)NLM091631106 |x 1099-1557 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:3 |g day:09 |g month:03 |g pages:352-365 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/pds.5567 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 3 |b 09 |c 03 |h 352-365 | ||